Acquisition

HLB to buy out HLB Life Science in $180M stock deal

What's the deal? HLB Co., Ltd. has agreed to acquire the remaining 83.02% stake in HLB Life Science Co., Ltd.Dealroom has a profile for this one. Try Dealroom → for roughly US$201.2M. The all-stock deal, announced November 20, 2026, will leave HLB owning 100% of its affiliate.

What's the structure? HLB is paying 0.085753 of its own common equity for each HLB Life Science share. Once complete, HLB Life Science will be absorbed and dissolved through a merger.

Why now? The move consolidates two listed entities under the HLB banner into a single company. HLB Life Science's board set up a special committee to review the transaction.

What's next? The deal needs antitrust clearance plus approval from both companies' boards and shareholders. Expected completion is July 1, 2027, with a provisional payment date of May 19, 2027.

Who's advising? E-Chon Accounting Corporation and Haekwang Law Firm advised HLB Life Science. Samdo Accounting Corporation's investment banking arm and Hyochun Law Firm advised HLB.

The signal: By folding its KOSDAQ-listed affiliate into the parent, HLB is simplifying a fragmented corporate structure — a common step as groups streamline ahead of broader strategic plays.

Read more: hk.marketscreener.com

Image credit: Generated with Gemini

More top stories